Literature DB >> 21932581

Italian pediatric data support hypothesis that simultaneous epidemics of type 1 diabetes and type 2 diabetes/metabolic syndrome/obesity are polar opposite responses (i.e., symptoms) to a primary inflammatory condition.

John B Classen1.   

Abstract

We previously postulated that iatrogenic inflammation caused epidemics of type 2 diabetes/metabolic syndrome/obesity by activating an immune suppressive cortisol response which protects against type 1 diabetes and other autoimmune diseases. In the current study, data on the incidence of obesity in different Italian provinces was compared with the incidence of type 1 diabetes in the same region. The association between obesity and type 1 diabetes was analyzed using Wilcoxon rank analysis. Results showed an inverse relationship; the regions with the highest rate of obesity (Campania and Lazia) were associated with a protective effect against type 1 diabetes. However, regions with the lowest rates of obesity were associated with the highest rate of type 1 diabetes. These results are consistent with previous analysis across different racial groups; races with high cortisol activity had an increased rate of type 2 diabetes but were protected from type 1 diabetes.

Entities:  

Mesh:

Year:  2011        PMID: 21932581     DOI: 10.1515/jpem.2011.023

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  2 in total

1.  Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection.

Authors:  Susan Costantini; Francesca Capone; Eliana Guerriero; Raffaele Marfella; Angela Sorice; Patrizia Maio; Michele Di Stasio; Giuseppe Paolisso; Giuseppe Castello; Giovanni Colonna
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

2.  The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes.

Authors:  Francesca Capone; Eliana Guerriero; Giovanni Colonna; Patrizia Maio; Alessandra Mangia; Raffaele Marfella; Giuseppe Paolisso; Francesco Izzo; Nicoletta Potenza; Luigi Tomeo; Giuseppe Castello; Susan Costantini
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.